Presence of the metabolic syndrome is associated with shorter time to castration-resistant prostate cancer

Annals of Oncology

Volumn 22, Issue 4, 2011, Pages 801-807

  Flanagan, J ^a,b   Gray, P Kathryn ^c   Hahn, N ^a   Hayes, J ^d   Myers, L J ^a,e   Carney Doebbeling, C ^a,f   Sweeney, C J ^a,d  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Kansas City Cancer Center   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f REGENSTRIEF INSTITUTE   (United States)

Author keywords

Hormonal therapy; Metabolic syndrome; Prostate cancer; Resistance

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; PROSTATE SPECIFIC ANTIGEN; TRIACYLGLYCEROL;

ADULT; AFRICAN AMERICAN; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BODY MASS; BONE METASTASIS; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CASTRATION; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; METASTASIS POTENTIAL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; RISK FACTOR;

EID: 79953328519     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq443     Document Type: Article

References (39)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Grundy SM, Brewer HB Jr, Cleeman JI et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438.
3. Koren-Morag N, Goldbourt U, Tanne D. Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack: a prospective cohort study in patients with atherosclerotic cardiovascular disease. Stroke 2005; 36: 1366-1371.
4. Malik S, Wong ND, Franklin SS et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245-1250.
5. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
6. Amling CL. Relationship between obesity and prostate cancer. Curr Opin Urol 2005; 15: 167-171.
7. Cowey S, Hardy RW. The metabolic syndrome: a high-risk state for cancer? Am J Pathol 2006; 169: 1505-1522.
8. Hammarsten J, Hogstedt B. Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer. 2005; 41: 2887-2895.
9. Fitzpatrick AL, Daling JR, Furberg CD et al. Hypertension, heart rate, use of antihypertensives, and incident prostate cancer. Ann Epidemiol 2001; 11: 534-542.
10. Giovannucci E, Rimm EB, Stampfer MJ et al. Height, body weight, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 1997; 6: 557-563.
11. Bravi F, Scotti L, Bosetti C et al. Self-reported history of hypercholesterolaemia and gallstones and the risk of prostate cancer. Ann Oncol 2006; 17: 1014-1017.
12. Laukkanen JA, Laaksonen DE, Niskanen L et al. Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study. Cancer Epidemiol Biomarkers Prev 2004; 13: 1646-1650.
13. Lund Haheim L, Wisloff TF, Holme I, Nafstad P. Metabolic syndrome predicts prostate cancer in a cohort of middle-aged Norwegian men followed for 27 years. Am J Epidemiol 2006; 164: 769-774.
14. Tande AJ, Platz EA, Folsom AR. The metabolic syndrome is associated with reduced risk of prostate cancer. Am J Epidemiol 2006; 164: 1094-1102.
15. Gong Z, Neuhouser ML, Goodman PJ et al. Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev 2006; 15: 1977-1983.
16. Scher HI, Eisenberger M, D'Amico AV et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the prostate-specific antigen working group. J Clin Oncol 2004; 22: 537-556.
17. Deedwania P, Barter P, Carmena R et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the treating to new targets study. Lancet 2006; 368: 919-928.
18. Huptas S, Geiss HC, Otto C, Parhofer KG. Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome. Am J Cardiol 2006; 98: 66-69.
19. Barnard RJ, Aronson WJ, Tymchuk CN, Ngo TH. Prostate cancer: another aspect of the insulin-resistance syndrome? Obes Rev 2002; 3: 303-308.
20. Chan JM, Stampfer MJ, Giovannucci E et al. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998; 279: 563-566.
21. DiGiovanni J, Kiguchi K, Frijhoff A et al. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci USA 2000; 97: 3455-3460.
22. Barnard RJ, Aronson WJ. Preclinical models relevant to diet, exercise, and cancer risk. Recent Results Cancer Res 2005; 166: 47-61.
23. Kaplan SA, Meehan AG, Shah A. The age related decrease in testosterone is significantly exacerbated in obese men with the metabolic syndrome. What are the implications for the relatively high incidence of erectile dysfunction observed in these men? J Urol 2006; 176: 1524-1527; discussion 1527-1528.
24. Robeva R, Kirilov G, Tomova A, Kumanov P. Low testosterone levels and unimpaired melatonin secretion in young males with metabolic syndrome. Andrologia 2006; 38: 216-220.
25. Baillargeon J, Platz EA, Rose DP et al. Obesity, adipokines, and prostate cancer in a prospective population-based study. Cancer Epidemiol Biomarkers Prev 2006; 15: 1331-1335.
26. Correia ML, Rahmouni K. Role of leptin in the cardiovascular and endocrine complications of metabolic syndrome. Diabetes Obes Metab 2006; 8: 603-610.
27. Onuma M, Bub JD, Rummel TL, Iwamoto Y. Prostate cancer cell-adipocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J Biol Chem 2003; 278: 42660-42667.
28. Goktas S, Yilmaz MI, Caglar K et al. Prostate cancer and adiponectin. Urology 2005; 65: 1168-1172.
29. Bonorden MJ, Rogozina OP, Kluczny CM et al. Intermittent calorie restriction delays prostate tumor detection and increases survival time in TRAMP mice. Nutr Cancer 2009; 61: 265-275.
30. Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol 2006; 97: 3A-11A.
31. Shariat SF, Andrews B, Kattan MW et al. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology 2001; 58: 1008-1015.
32. Schenk S, Saberi M, Olefsky JM. Insulin sensitivity: modulation by nutrients and inflammation. J Clin Invest 2008; 118: 2992-3002.
33. Smith MR, Lee H, McGovern F et al. Metabolic changes during gonadotropinreleasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 2008; 112: 2188-2194.
34. Knowler WC, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
35. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. Increased cancerrelated mortality for patients with type 2 diabetes who use sulfonylureas or insulin: response to Farooki and Schneider. Diabetes Care 2006; 29: 1990-1991.
36. Jiralerspong S, Palla SL, Giordano SH et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 2009; 27: 3297-3302.
37. Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 2009; 20: 1617-1622.
38. Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766-1777.
39. Tan BK, Adya R, Chen J et al. Metformin decreases angiogenesis via NF-kappaB and Erk1/2/Erk5 pathways by increasing the antiangiogenic thrombospondin-1. Cardiovasc Res 2009; 83: 566-574.